Cargando...
Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells
Trastuzumab (Herceptin(®)) is an effective targeted therapy in HER2 overexpressing human breast carcinoma. However, many HER2-positive patients initially or eventually become resistant to this treatment, so elucidating mechanisms of trastuzumab resistance that emerge in breast carcinoma cells is cli...
Gardado en:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2012
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3577983/ https://ncbi.nlm.nih.gov/pubmed/23248119 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-12-2149 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|